Trial Profile

Improved Drug Eluting Stent for Percutaneous Coronary Intervention of the Left Main Artery in a Real World All-comers Population

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Aspirin; Clopidogrel; Prasugrel; Ticagrelor
Indications Coronary artery disease
Focus Therapeutic Use
Acronyms IDEAL-LM

Most Recent Events

01 May 2017 Rationale and study design, published in the American Heart Journal.
21 Mar 2016 Accrual to date is 26% as reported by United Kingdom Clinical Research Network.
11 Dec 2015 Accrual to date is 19% as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com